Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-15

Research on breast cancer aimed at identifying unique antigens and at developing antibodies

Obiettivo

The department of Oncology of Crucell Holland BV, lead by Renate Zwijsen (PhD) is actively involved in the development and the commercialisation of monoclonal human antibodies, applying its MAbstract target discovery and antibody development technology and its PER.C6 human cell line technology for high-yielding antibody production.

The department of Oncology intends on initiating a breast cancer research program aimed specifically at identifying antigens that are uniquely expressed in breast cancer and, thereafter, at developing human antibodies that selectively bind to these identified antigens. For this project, Crucell Holland BV has an exclusive arrangement with the University Medical Centre of Utrecht (UMC Utrecht) through which Crucell Holland BV will have a constant supply of fresh breast cancer tissue samples to be used for this research project.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Dati non disponibili

Invito a presentare proposte

IHP-MCHI-01-1
Vedi altri progetti per questo bando

Meccanismo di finanziamento

Dati non disponibili

Coordinatore

CRUCELL HOLLAND B.V.
Contributo UE
Nessun dato
Indirizzo
Archimedesweg 4
LEIDEN
Paesi Bassi
Costo totale
Nessun dato